Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI versus IRIS as Second-Line Chemotherapy for Unresectable Colorectal Cancer
jRCT1080220199Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan, fluorouracil, levoleucovorin and tegafur in colorectal cancer (CRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
irinotecanfluorouracillevoleucovorintegafur
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1080220199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220199.